share_log

Innovid Corp. (NYSE:CTV) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Innovid Corp. (NYSE:CTV) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Innovid corp.(紐交所:CTV)剛剛發佈了其第二季度業績:以下是分析師的看法
Simply Wall St ·  08/09 20:16

It's been a mediocre week for Innovid Corp. (NYSE:CTV) shareholders, with the stock dropping 18% to US$1.68 in the week since its latest quarterly results. It was a pretty bad result overall; while revenues were in line with expectations at US$38m, statutory losses exploded to US$0.07 per share. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

Innovid Corp. (NYSE:CTV) 股票在最新季度業績公佈以來的一週內下跌了18%,至1.68美元,對股東來說是一箇中規中矩的一週。總體上,這是一個相當糟糕的結果; 雖然營收達到了預期的3800萬美元,但標準法下虧損額激增至每股0.07美元。在公佈業績後,分析師們更新了其盈利模型,知道他們是否認爲公司前景出現了強烈變化,或仍是業務慣例,將是好事。考慮到這一點,我們收集了最新的法定預測,查看分析師們對明年的預期。

big
NYSE:CTV Earnings and Revenue Growth August 9th 2024
2024年8月9日紐交所:CTV的盈利和營收增長。

Taking into account the latest results, the consensus forecast from Innovid's three analysts is for revenues of US$160.0m in 2024. This reflects a reasonable 7.0% improvement in revenue compared to the last 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 22% to US$0.11. Before this earnings announcement, the analysts had been modelling revenues of US$160.8m and losses of US$0.047 per share in 2024. While this year's revenue estimates held steady, there was also a regrettable increase in loss per share expectations, suggesting the consensus has a bit of a mixed view on the stock.

考慮到最新的業績,Innovid的3位分析師的共識預測爲2024年營業收入爲16000萬美元。與過去12個月相比,營收合理地提高了7.0%。預計每股虧損將在不久的將來大幅縮減,降至0.11美元,縮小了22%。在此次盈利公告之前,分析師們曾對2024年的營收進行建模,營收爲16080萬美元,每股虧損爲0.047美元。雖然今年的營收預測保持穩定,但失業每股的預期也出現了可惜的增加,這表明共識對股票有點複雜的看法。

The consensus price target held steady at US$2.83, seemingly implying that the higher forecast losses are not expected to have a long term impact on the company's valuation. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Innovid analyst has a price target of US$3.00 per share, while the most pessimistic values it at US$2.50. The narrow spread of estimates could suggest that the business' future is relatively easy to value, or thatthe analysts have a strong view on its prospects.

共識價格目標保持穩定在2.83美元,似乎意味着更高的預測虧損不會對公司的估值產生長期影響。共識價格目標僅是個人分析師目標的平均值,因此看看基本估計的範圍有多寬會很有用。最樂觀的Innovid分析師的股價目標爲3.00美元,而最悲觀的則在2.50美元。估計的狹窄範圍可能表明該業務的未來相對容易估價,或者分析師對其前景有強烈看法。

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. It's pretty clear that there is an expectation that Innovid's revenue growth will slow down substantially, with revenues to the end of 2024 expected to display 14% growth on an annualised basis. This is compared to a historical growth rate of 20% over the past three years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 3.3% annually. So it's pretty clear that, while Innovid's revenue growth is expected to slow, it's still expected to grow faster than the industry itself.

我們可以通過將這些估計與過去的業績以及預測與行業其他公司相對看漲或看跌進行對比等大局觀的方式來看待這些估計。很明顯,預計Innovid的營收增長將大幅放緩,在2024年底預計以年均14%的速度增長。而過去三年的歷史增長率爲20%。相比之下,該行業中其他受到分析師關注的公司預計每年營收增長率爲3.3%。因此,儘管預計Innovid的營收增長將放緩,但仍預計比整個行業增長速度更快。

The Bottom Line

最重要的事情是分析師增加了它對下一年每股虧損的估計。令人欣慰的是,營收預測未發生重大變化,業務仍有望比整個行業增長更快。共識價格目標穩定在28.50美元,最新估計不足以對價格目標產生影響。

The most important thing to note is the forecast of increased losses next year, suggesting all may not be well at Innovid. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

需要注意的最重要的事情是明年預計會增加虧損,這表明Innovid可能存在問題。幸運的是,它們還確認了其營收數字,表明其跟蹤符合預期。此外,我們的數據表明,營收預計將比本行業整體增長更快。共識價格目標沒有真正變化,這表明估值的內在價值沒有因最新的估計發生重大變化。

With that in mind, we wouldn't be too quick to come to a conclusion on Innovid. Long-term earnings power is much more important than next year's profits. We have estimates - from multiple Innovid analysts - going out to 2026, and you can see them free on our platform here.

考慮到此,我們不應該過於快速得出結論。長期盈利能力比明年的利潤更重要。我們有來自多位Innovid分析師的估計,可延伸至2026年,您可以在這裏免費查看它們。

Even so, be aware that Innovid is showing 2 warning signs in our investment analysis , you should know about...

即使如此,請注意,Innovid在我們的投資分析中顯示了2個警告信號,您應該了解......

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論